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3. Abstract 
 
In 2006 Kenya began implementing its new anti-malarial treatment policy that replaced 
sulphadoxine/ sulfalene-pyrimethamine (SP) with a more efficacious artemisinin-based 
combination therapy (ACT), artemether-lumefantrine (AL). The treatment is being distributed 
through the public sector free of charge but the level of access to AL remains low. The aim of 
this study is to evaluate to what extent the provision of pre-packed, subsidized AL delivered 
through private sector retailers will increase the proportion of children under five, with fever, 
receiving appropriate anti-malarial treatment. The intervention will be implemented by the 
Division of Malaria Control (DOMC) in collaboration with Population Services International 
(PSI). KEMRI/ Wellcome Trust Research Program (KWTRP) will be responsible for the 
evaluation of the intervention. The effectiveness of this intervention will be evaluated through a 
pre-post cluster randomised controlled trial. Baseline data will be collected before the 
intervention and follow up data 9 months after the start of the intervention from both households 
and retail outlets. The outcomes monitored will be derived from a list of key indicators approved 
by the DOMC as information they require to inform their policies on increasing access to ACTs. 
The data will be collected using six data collection activities: 1) Retail census, 2) Household 
survey, 3) Provider survey, 4) Mystery shopper, 5) Focus group discussions, and 6) 
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Documentation of context. The results from this study will support the DOMC in national 
strategic planning for improving access to effective malaria treatment. 
 
4. Introduction 
 
a) Malaria Background   
Malaria remains an important health problem with more than 3 billion individuals living at risk 
of the disease [1]. It is estimated that 300 to 660 million cases are caused by the most virulent of 
the plasmodium species, Plasmodium falciparum [2]. P. falciparum contributes to 90% of the 
malaria burden in Africa and 1 million childhood deaths per year are a direct consequence of the 
parasitic infection [2, 3]. In Kenya, approximately 20 million people live in areas that expose 
them to the risk of developing malaria. By 1997, it was estimated that 145,000 children aged 
between 0-4 years were admitted to hospital from this disease annually and 26,000 died [4]. 
Although there has been a recent decline in cases, the numbers remain unacceptably high [5]. 
 
The Roll Back Malaria (RBM) Global Partnership was created in 1998 to increase international 
awareness of malaria and rally support for the control of the disease [6]. One of its four core 
targets is that ‘80% of those suffering from malaria should receive appropriate treatment within 
24 hours by 2010’ [7]. The rapidly increasing resistance to widely used and inexpensive anti-
malarials, as well as the inability of the health care sector to provide sufficient services to all 
those who need care have created barriers to achieving this goal in many parts of Africa, 
including Kenya [8, 9]. 
  
b) The Policy Change in Kenya 
Artemisinin derivatives used in combination with other effective anti-malarial treatments are 
currently considered very effective, with cure rates of over 90% [10]. They have been shown to 
be well tolerated and to lower transmission rates within communities by reducing gametocyte 
loads.  It is thought that the rate of development of resistance to this treatment will be greatly 
reduced because of the short half life of artemisinin and its use in combination with other 
treatments [11, 12]. To date, 56 countries have incorporated ACTs into their malaria treatment 
guidelines [13].  
 
Due to a precipitous decline in its clinical efficacy SP was replaced with AL for the treatment of 
uncomplicated malaria in Kenya [14, 15]. Kenya changed its anti-malarial treatment policy in 
2004 with public sector distribution of AL beginning mid 2006. The policy change process in 
Kenya was to occur in phases over a five year period with the first two years seeing AL 
distributed free of charge through public facilities. This would allow time for the country to 
develop experience before the policy could be rolled out to a wider range of providers such as 
private-for profit clinics and the retail sector in order to increase access [14, 15]. 
 
c) Treatment of Malaria within the Public and Private Sector  
After more than a year of distributing AL free of charge within the public sector, studies carried 
out in Kenya revealed that only 26% of children presenting with fever in public health facilities 
who would benefit from this treatment were prescribed it. This is despite interventions such as 
in-service training and awareness campaigns implemented to promote uptake [16]. This poor 
adherence to guidelines is consistent with findings in other parts of Africa, such as Zambia where 
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after one year of policy implementation in the public sector, AL was only prescribed for 22% of 
febrile children [17-22]. According to a recent evaluation of the Kenyan public sector, weak 
product supply chains, poor training and supervision as well as a lack in health care workers’ 
prescribing confidence are all thought to have contributed to poor prescribing practices [23]. 
Weaknesses within the public sector have been acknowledged by the government who are 
working in collaboration with both local and international organisations to improve performance 
[24]. 
 
Even if a majority of children accessing care within the public sector received AL, the treatment 
seeking behaviour patterns in Kenya are such that a significant proportion of healthcare is first 
sought through the private sector [25-28] (see typology of health care providers in Table 1).  
 
Table 1: Health Care Providers in Kenya – a Typology 
 
Sector Definition Constitutes 
Public Providers funded by and in direct 
control of the government 
 Government health care facilities 
 Community Owned Resource Persons 
Private Providers who fall outside the direct 
control of and are not funded by the 
government 
 Not for profit (Mission and Non-governmental 
organization) health care facilities and community 
owned resource persons 
 Private/ commercial health care facilities 
 Retailers: registered pharmacies, general 
provision shops and mobile hawkers  
 Traditional healers and herbalists 
 
A household survey carried out in four endemic districts in Kenya revealed that 90% of 
caregivers took some action to treat a child’s fever within 48 hours of symptom onset. Of these, 
47% first sought treatment in the private retail sector and only 35% went to public or not for 
profit health facilities [27]. A small proportion, 23.3% of all these fevers were treated with an 
anti-malarial within 48 hours, of which 61% were obtained from the public sector, 28% from the 
retail sector and only 10% by self administration of medicines available in the household. The 
proportion of febrile children who received first line recommended AL within 48 hours was only 
10.2%. As expected, the majority of AL (95%) was dispensed from public health facilities [27]. 
What this demonstrates is that health care for malaria is heavily sourced from the private retail 
sector; however, the services received tend to be poor. Care provided from this sector for the 
treatment of malaria is mainly based on ineffective medications [25-27]. Since a high proportion 
of individuals seek treatment within the retail sector [29-31], encouraging AL distribution within 
this sector at an affordable price, along with improving the quality of health care services offered 
is expected to significantly expand the coverage of effective malaria treatment within the 
community [32].  
 
d) Improving Delivery of Anti Malarials through Retailers  
Home Management of Malaria (HMM) is a strategy that has been supported by RBM with the 
aim of increasing prompt and effective treatment of malaria within the community. This strategy 
exploits the strengths and improves the services offered by providers outside the public facilities. 
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It can be delivered through retailers, community health workers or other community members 
and is generally implemented alongside public sector facility delivery [6, 31, 33-52]. 
 
HMM in the retail sector can be broken down into various intervention components which 
include training and capacity building; demand generation/ consumer information; quality 
assurance and the creation of an enabling environment. Previous pilots carried out on HMM 
interventions within the retail sector show that they are more successful if they begin with a 
comprehensive situation analysis to understand the legal and market environment of the retail 
sector; if they involve all the necessary stakeholders from the retailers to public health officials; 
if the strategy consists of a combination of approaches; and if the interventions are on-going to 
ensure sustainability of outcomes [6, 31, 33-51]. 
 
Studies have been carried out to evaluate the value of HMM within the retail sector however, the 
evidence remains limited. A number of HMM interventions based on ACTs are currently 
underway in Tanzania, Uganda, Rwanda, Cambodia, Madagascar and Nigeria. Preliminary 
results from the ACT pilot in Tanzania indicate that delivery of ACT through retailers increased 
uptake of the medication, but access of the medication to those in lower socio economic quintiles 
remained poor (unpublished data from the Clinton Foundation Tanzania Pilot ACT Study, 2007). 
However, no evaluations have yet been completed and none are yet underway in Kenya. 
 
Previous HMM studies have focused on other anti-malarial therapies such as SP, however the 
nature of the dosing and cost of ACTs may alter the outcomes of the interventions. Moreover, 
many evaluations focus on intermediate outcomes such as provider knowledge and behaviour 
rather than more health related outcomes such as medicine use within the community. In 
addition, the outcomes measured vary between studies making comparability difficult [32, 52, 
53]. No studies have used a cluster randomised approach, and most studies do not even include a 
control group, relying instead on pre and post data only [32, 53]. This may have exposed studies 
to possible confounders.  Since very few studies have evaluated outcomes by socio-economic 
status, there is little information on how equitable these interventions are [32]. Also, many 
studies have evaluated outcomes soon after implementation of the interventions (3-4 months) so 
the sustainability of these programs and their long term effectiveness remain unknown [32, 53]. 
There has only been one comprehensive cost-effectiveness analysis of HMM carried out in 
Kenya [54], therefore little is known on how much the government should budget to roll out 
HMM interventions on a national scale and the relative value for money of these strategies. 
Lastly, very few pilots have been published in peer reviewed journals, thus the quality of the data 
available may be questionable [32, 53]. 
 
5. Justification for Study 
 
Kenya has planned to roll out AL into the private sector in 2009 [14] however this decision 
should be based on sound evidence. Even with the information available from the previous 
monotherapy retail sector interventions, many key questions regarding HMM interventions and 
the distribution of AL through the private retail sector remain unanswered. These include a) can 
retailers provide AL in an appropriate manner, and b) will HMM interventions within the private 
retail sector significantly improve access to AL in Kenya, and in an equitable way. It is hoped 
that this and other HMM pilots, based on common outcome measures will be carried out in 
Kenya to address these questions and augment the data that are already available. All these data 
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can then be collated to provide substantial evidence that can be used by policy makers to guide 
their decisions on if and how to distribute AL outside of public facilities.  
 
6. Null Hypothesis 
 
The provision of pre-packaged, subsidized, AL delivered through private sector retailers will 
have no effect on improving the coverage of prompt effective anti-malarial treatment. 
 
7. Objectives 
 
7a) General Objectives  
 
To evaluate to what extent the provision of pre packaged, subsidized, AL delivered through 
private sector retailers will improve the coverage of prompt effective anti-malarial treatment. 
 
7b) Specific Objectives 
 
1) To determine the impact on the proportion of children under five with fever being treated 
promptly with appropriate anti-malarial treatment, and adhering to the correct dose 
(accessibility and utilisation). 
 
2) To determine if private sector retailers can deliver AL to appropriate standards of quality 
for the treatment of fever in children under five years (provision). 
 
3) To determine distribution of benefits of retail sector delivery of AL by socio- economic 
status (equitable coverage). 
 
4) To explore reasons for the impact observed and identify any challenges in the 
implementation process (explanation of experience). 
 
8. Design and Methodology 
 
General Study Design 
 
The study design employs a pre-post randomised cluster controlled design, with clusters (sub 
locations) randomly allocated to intervention and control groups
1
. 9 intervention and 9 control 
sub locations will be located across 3 districts in Western province. In the intervention areas, pre-
packed, subsidized paediatric AL will be introduced in September 2008 through selected private 
sector retailers serving the sub location population, together with a range of supportive activities 
(see below). Public sector delivery will continue as normal. In the control sub locations, routine 
delivery of AL through public sector outlets will also continue as normal. Control and 
intervention areas will be selected with consideration of geographic proximity to ensure that the 
control areas are not ‘contaminated’ by the intervention. Baseline data collection will take place 
                                                          
1
 The effectiveness of the intervention will be measured as the difference in differences between the baseline and 
follow-up surveys in the intervention and control groups. 
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in July-August 2008 and the post intervention data collection will occur in July-August 2009. 
These survey dates are considered to coincide with peak malaria season and therefore have been 
selected to maximise the number of fevers identified.  
 
The Intervention Package 
 
The intervention package will be designed and implemented by the DOMC in collaboration with 
Population Services International (PSI), Ministry of Health (MOH) staff at the province and 
district level and other key stakeholders. The role of KEMRI/ Wellcome Trust Research Program 
(KWTRP) will be limited to evaluation. PSI is a non profit organisation that promotes healthy 
behaviour through the use of health marketing programs. Its main focus is on malaria, family 
planning, HIV/AIDS/STI prevention, diarrhoeal diseases, micronutrient deficiencies and 
waterborne disease. PSI will draw from their previous experiences from the delivery of retail 
sector ACT in a number of countries including Tanzania, Rwanda, Cambodia, Madagascar and 
Nigeria. A brief summary of the intervention is described below. A more detailed intervention 
plan will be developed in collaboration with the above stakeholders. 
 
The Product – Pre-packaged AL for children under 5: PSI and the DOMC will develop a 
branded pre-packaged AL product for the treatment of malaria in children. In line with dosing 
recommendations, two doses will be developed; one for 6 months to 3 year olds (5-15kg) and 
one for 4 to 8 year olds (15-25kg). The target group for this intervention will be children under 
five years of age. The product’s outer packaging and insert will use locally developed low 
literacy instructions to improve appropriate dose recognition by caregivers and shopkeepers and 
promote adherence to the full regimen. The process of product development will be based on 
extensive formative research, pre-testing and modification in consultation with the case 
management team of the DOMC. The product’s instructions will also include details on the 
Integrated Management of Childhood Illness (IMCI) danger signs and the need to refer to the 
public health service severe conditions and children under one year
2
.  
 
Price: It is proposed that the consumer price of the pre-packaged AL will be competitive with 
the currently available SP and amodiaquine (AQ) brands of malaria treatment. This price is 
envisaged to be approximately 20 Kenya Shillings (Ksh) per treatment course for all under five 
doses. This approach will ensure that price is not a significant barrier to accessing effective anti-
malarial treatment and that there is no significant price incentive for consumers to choose an 
inappropriate malaria treatment. This price will also undercut artemisinin monotherapies 
substantially meaning that we can expect demand for them to be reduced in the intervention sites. 
The price will be clearly shown on the packaging and will be widely promoted in 
communications to encourage adherence.  
 
Place/Distribution: The pre-packaged product will be distributed directly to selected retail 
outlets on a routine basis. Outlets selected will be those that are perceived to be well established, 
respected businesses by the local community. These outlets should already stock anti-malarials 
                                                          
2  Note that whilst the AL formulation is suitable for children under 1 year but over 5kg, the proposed program will promote all 
under 1’s to be referred to the nearest health facility.   This is because of the increased risk of progression to severe malaria and 
hence, vulnerability of this age group. Guidelines will be included in the packaging for under ones, directing how to use the 
medicine in an emergency, so long as the child is over 5kg, so that treatment can commence, buying time until professional 
medical care can be sought. 
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or anti-pyretics and have been functioning for a specified minimum amount of time (to be 
defined following initial retail census). Selected outlets will have a notice visible to consumers 
informing them that the pre-packaged AL can be purchased from the store, which will tie into 
promotional activities.  
 
Shopkeeper training: All selected shopkeepers will be given brief focused training. 
Shopkeepers will be trained to ask key questions related to symptoms and age of the child which 
will form the basis of their response in terms of referral to a public health facility or supply of an 
appropriate prepackaged dose of AL, combined with key messages on administering the 
treatment and adhering to the regimen. The content of the shopkeeper training will be based upon 
the experiences of the extensive shopkeeper training studies already undertaken in Kenya by the 
Ministry of Health (MOH) and KEMRI/ Wellcome Trust Research Programme (KWTRP) [55, 
56]. Shopkeepers will be trained on appropriate storage conditions of AL as well as identifying 
IMCI danger signs, and the need to refer specific conditions to public health facilities. The 
trainings will integrate local nurses as technical advisors.  PSI will develop training, point of sale 
materials, and job aids including simple treatment algorithms with guidance from the DOMC and 
the drug policy technical working group (DPTWG) to improve the quality and quantity of 
information provided to consumers.   
 
Promotion: PSI will carry out a series of promotional activities in the intervention areas and 
related dominant market centres. Messages will target caregivers of children under five and will 
promote appropriate treatment seeking behaviour including the benefits of AL and its availability 
both in public sector facilities and identified private sector outlets. Messages will be delivered 
through a range of interpersonal communications media including community drama, road 
shows, chief’s barazas, and community group educational sessions. MOH public health 
technicians will also be briefed on the program and encouraged to conduct community awareness 
programs and integrate messages into health talks. In addition, where there are active district ITN 
advocacy/ information, education and communication (IEC) working groups, their support will 
be sought in conducting awareness raising in the targeted communities. These activities will be 
supported by point of sale materials, posters, leaflets and localized media such as wall paintings 
(mass media strategies will not be used in this pilot phase to avoid contamination between 
intervention and control areas). 
 
Diagnosis: Diagnosis of malaria within the retail outlets will be based on a history of fever, as is 
standard practice in a majority of endemic rural public health facilities and stated in the World 
Health Organisation (WHO) guidelines [57, 58]. Shopkeepers will be educated on this through 
training and IEC material. 
 
Drug Regulation: AL is currently registered in Kenya as a prescription only medicine (POM). 
However, the transitional plan for implementation of the ACT Malaria Treatment Policy in 
Kenya states that AL should eventually be deregulated and that studies must be conducted to 
guide this process. PSI, KWTRP and the DOMC will seek exemption from the POM regulation 
for this pilot.  
 
Pharmacovigilance: The Pharmacy and Poisons Board (PPB) have developed guidelines and 
tools for the collection of pharmacovigilance data on AL since its release in the public sector. 
The intervention package will therefore be implemented in collaboration with the PPB to ensure 
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that pharmacovigilance requirements are met. Shopkeepers will be educated on possible adverse 
effects and will advise caregivers to seek care from the nearest health facility for any suspected 
adverse drug reactions (ADRs). The shopkeeper will complete a CHW referral form for each 
such caregiver; one copy will be taken by the caregiver to the facility and the other copy will 
remain with the shopkeeper and later collected and sent to the PBB. All ADRs seen within health 
facilities will be reported back to the PPB. The PPB along with district investigation teams will 
be involved in following up any serious ADRs. The DOMC and PSI will work together with the 
PPB and provincial pharmacist to ensure staff in health care facilities within the province receive 
training on pharmacovigilance with regards to AL and to make them aware of the pilot.  
 
8a) Study Sites 
 
The study will take place in rural areas of 3 districts in Western Province. This province was 
selected for the following reasons: 
 
 It is malaria endemic (Figure 1), 
 PSI has a strong team of permanent sales staff on the ground3, 
 There are no other planned HMM interventions4, 
 Presence of a relatively active retail market. 
 
Within Western province, Bungoma district was excluded because of the extent of previous 
malaria-related interventions which may make it atypical. Mount Elgon district was excluded 
because of the current political insecurity in that area. The districts chosen for the pilot were 
therefore Butere/ Mumias, Teso and Busia (Figure 1). Butere and Mumias were officially 
divided into two districts in mid 2007, but because this split is recent, the two districts will be 
treated as one for the purposes of this study.  
 
The pilot intervention will be implemented at the sub-location level. The sub-location was 
selected for the following reasons: 
 
 To provide a reasonable scale for implementation, 
 To ensure no contamination between intervention and control (which would be more likely if 
larger areas were used), 
 To contain the total medicine cost for the pilot phase. 
 
The following inclusion criteria were used for selecting intervention and control sub-locations: 
 
 They are rural, as this is where access to health care is most limited and so HMM most 
needed. In addition retailers in urban and peri-urban sub-locations serve customers from a 
much wider area, which would lead to contamination;  
 The populations within the sub-locations are between 2,500 to 10,000; smaller sub-locations 
were excluded to ensure there was a reasonable scale for implementation and adequate 
                                                          
3
 PSI staff in Coast Province are much more limited, especially in rural areas. 
4
 The Great Lakes University plan to implement an HMM intervention using community health workers in Nyanza 
Province. 
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sample sizes for the evaluation; larger sub-locations were excluded to contain the cost of the 
pilot.  
 
Through random selection 18 sub-locations were identified, stratified across the 3 districts, each 
district having 3 controls and 3 interventions (Figure 2-4). To avoid contamination a buffer of at 
least 2 sub-locations was maintained between any selected sub-location. The sub locations 
shown below are the outcomes from our preliminary sample selection. The final selection will be 
confirmed after further visits to the areas by PSI to investigate feasibility. 
 
 
 
Figure 1: Map of Kenya displaying district boundaries and malaria classifications. Butere/ 
Mumias, Teso and Busia are the chosen sites for the pilot.  
 
 
 
 
 
 
 
 
 
Teso    
 
 
 
 
Busia 
 
 
 
Butere/ 
Mumias 
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Figure 2 (left): Map of Busia 
district showing control (orange) 
and intervention (green) sub 
locations. 
 
N.B: ‘Other’ (see Legend) refers 
to all sub locations that do not fit 
the sub location criteria (e.g. 
urban or peri-urban and with 
populations <2,500 and > 10,000). 
Figure 3 (left): Map of Teso 
district showing control (orange) 
and intervention (green) sub 
locations. 
 
N.B: ‘Other’ (see Legend) refers to 
all sub locations that do not fit the 
sub location criteria (e.g. urban or 
peri-urban and with populations 
<2,500 and > 10,000). 
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Table 2: District Demographics 
 
 BUSIA TESO BUTERE/ MUMIAS 
NO. OF SUB LOCATIONS 99 83 79 
% OF SUB LOCATIONS RURAL 76 66 75 
% HOUSEHOLD HEADS 
COMPLETED PRIMARY 
SCHOOL 
57 54 58 
NO OF HEALTH CARE 
FACILITES* 
39 21 51 
%POOR (RANGE ACROSS SUB 
LOCATIONS) 
67 (53-74) 50 (44-68) 62 (53-73) 
EST POP 2007 (AVERAGE PER 
SUB LOCATION) 
370,608 (4,964) 227,058 (2,769) 573,275 (7,350) 
POP_ DENSITY/ KM
2
 433 406 611 
* These include Ministry of Health and other ministries, mission and non-governmental health facilities 
 
Table 2 gives an overview of the districts’ demographics. Teso is the least poor district with 50% 
of the population living under the poverty line, followed by Butere/ Mumias, with Busia being 
the least well off. Butere/ Mumias is the district with the largest population, Teso is the least 
populated, containing around half the population of Butere/ Mumias. Butere/ Mumias is also the 
most densely populated district with 611 people per KM
2
. The number of health care facilities 
are greatest in Butere/ Mumias followed by Busia and then Teso. In all three districts just over 
50% of household heads have completed primary school. The languages spoken in Busia and 
Figure 4 (left): Map of Butere/ 
Mumias district showing control 
(orange) and intervention (green) 
sub locations. 
 
N.B: ‘Other’ (see Legend) refers to 
all sub locations that do not fit the 
sub location criteria (e.g. urban or 
peri-urban and with populations 
<2,500 and > 10,000). 
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Butere/ Mumias include Luo, Kiswahili and different dialects of Luhya, and in Teso, Luhya, 
Kiteso and Kiswahili.  
 
Previous malaria control initiatives such as training of shopkeepers and community awareness 
programmes have been carried out in Busia by both the Ministry of Health and Non 
Governmental Organisations (NGOs). The DOMC and PSI will be intervening in all these 
districts to implement malaria community awareness programs and train public facility health 
care staff, funded by the President’s Malaria Initiative (PMI). These activities will cover both 
pilot intervention and control areas, and take place after baseline data collection for this study 
has been completed. This allows us to assess the value added of retail sector provision once 
appropriate efforts to strengthen the public sector have been put in place. A more detailed 
context analysis will take place during the pilot to identify other health initiatives within the 
districts that may affect the outcomes of the pilot.  
 
Table 3: Demographics for the selected sub locations 
 
SUB_LOCATION DISTRICT %POOR UNIQUE_ID^ ESTPOP2007 POP_ DENSITY/ KM
2
 ARM 
MAGOMBE 
CENTRAL 
BUSIA 64 89 3575 200 Control 
KANJALA BUSIA 68 36 2703 389 Control 
NANDEREMA BUSIA 66 74 3490 298 Control 
MUYAFWA BUSIA 65 34 4053 473 Intervention 
LUPIDA BUSIA 68 2 4418 328 Intervention 
SIKINGA BUSIA 69 10 5945 392 Intervention 
AKACHACHATA TESO 48 23 2626 293 Control 
APOKOR(ANGURAI) TESO 51 2 3185 374 Control 
KAMUNUOIT TESO 49 61 3273 297 Control 
ALUDEKA TESO 48 48 3275 285 Intervention 
OKATEKOK TESO 52 75 3955 375 Intervention 
KAKALET TESO 49 18 3370 372 Intervention 
SHIANDA(BM) BUTERE/MUMIAS 58 61 3030 748 Control 
BUCHIFI BUTERE/MUMIAS 61 27 8659 574 Control 
MUSAMBA BUTERE/MUMIAS 62 3 8079 476 Control 
ESHIBINGA BUTERE/MUMIAS 69 71 4134 643 Intervention 
LUNZA BUTERE/MUMIAS 61 31 9294 482 Intervention 
MALAHA(BM) BUTERE/MUMIAS 63 18 6094 612 Intervention 
^Represents the numbers assigned to the sub locations on the district maps 
 
Table 3 shows the demographics for the selected sub-location populations, the unique ID 
represents the numbers of the individual sub-location on the district maps (Figures 2-4). These 
data reflect the experience at the sub location level. The populations within the selected Teso 
sub-locations tend to be less poor than the other two districts, with the percentage living below 
the poverty line ranging from 48-52%.  In Busia the percentage living under the poverty line 
ranges from 64-69% while in Butere Mumias it is from 58 to 69%. Butere Mumias is the most 
densely populated with sub-location population densities ranging from 476 to 748 per KM
2
. 
Busia and Teso’s population densities are quite similar with Teso ranging from 293-374 per KM2 
and Busia from 200 to 473 per KM
2
. Across the three districts, the average % poor and 
population densities between the control and intervention sub locations are similar (Table 4). 
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Table 4: Comparison of Percentage Poor and Population Density between Intervention and 
Control Sub Locations, across all three Districts. 
 
ARM 
AVERAGE 
%POOR 
AVERAGE POP_ DENSITY/ 
KM2 
CONTROL SUB LOCATIONS 58 4291 
INTERVENTION SUB LOCATIONS 60 4949 
  
 
Retail outlets can either be found within a market centre where there is a group of shops together 
or outside of market centres as ‘stand alone’ or individual shops. There are on average 8 retail 
outlets in a market centre. Based on study visits and discussions with PSI and MOH staff, it is 
estimated that an average of 8-10 ‘stand alone’ retail outlets and 3-4 market centres containing 
retail outlets sell medicines to a rural sub-location in Busia; in Butere/ Mumias around 15-18 
‘stand alone’ retail outlets and 5-6 market centres, while in Teso it is about 12-14 ‘stand alone’ 
retail outlets and 5-6 market centres. These details will be confirmed by further visits by PSI and 
through the initial retail census (see below) to be carried out by KWTRP.  
 
8b) Study Populations 
 
A total of six data collection activities will be conducted to evaluate the intervention. Specific 
study populations for each activity are listed below.   
 
i) Criteria for inclusion of subjects: see under specific surveys below 
 
ii) Criteria for exclusion of subjects: see under specific surveys below 
 
iii) Rationale for animal use and justification for animal species chosen: not applicable 
 
8c) Sampling 
 
i) Sampling size determinations: see under specific surveys below 
 
ii) Sampling procedures: see under specific surveys below 
 
8d) Procedures 
 
i) Description of the type of data to be collected and the collection procedures to be 
followed 
 
A list of key indicators for all pilots has been developed in collaboration with the DOMC, and 
were approved by them (Appendix 4). They have been divided into compulsory and optional 
indicators. The indicators have been identified through consideration of relevant DOMC targets; 
Global Fund indicators; Roll Back Malaria monitoring and evaluation reference group indicators; 
and Global ACT subsidy monitoring and evaluation frameworks. The compulsory indicators are 
to be monitored by all pilots evaluating interventions to increase anti-malarial access outside the 
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public sector within Kenya. Standardizing outcome measures between pilots will allow for data 
to be compared across studies, and will also ensure that the studies provide the DOMC with the 
relevant information they require for policy implications. The Red Cross will also run an HMM 
pilot based on these indicators, other future pilots are to be developed.  
 
In this study we will focus on the compulsory indicators and some optional indicators that we 
consider to be relevant to monitoring the effect of the intervention. As previously mentioned, 
these indicators will be monitored through 6 data collection activities, each with its own data 
collection tool (Figure 5).  
 
 
Figure: 5: Data Collection Activities 
 
     Household Survey                                                                                         Retail Census                                                          
 
 
 
     Household Level                       Focus Group Discussions                 Retail Outlet Level              Provider 
                                                                                                                                                                             Survey                                                                               
                                                                   
 
 
                                                                                                                                           Mystery Shopper 
 
 
 
    Documentation of context                          District                             
                                                                 Level                              
 
 
The tools for each activity have drawn on studies which have evaluated similar outcomes within 
the retail sector and the household level [27, 60-62]. The tools will be piloted before the studies 
to ensure questions are interpreted correctly by the respondents. The household survey, retail 
census, provider survey and mystery shopper survey will be administered both before and after 
the interventions in both the intervention and control areas. The focus group discussions will 
only be administered post intervention and only in the intervention areas. Data collection for the 
documentation of context will be on-going throughout the evaluation. 
 
1) Retail Census Survey:  
 
The retail census aims to identify all retail outlets selling medicines that serve the population of 
the study sub-locations. This will include retail outlets located both within the study sub-
locations and those in neighbouring sub-locations that are frequently used by the study 
population. For the purposes of this study, retail outlets include all shops selling medicines, 
including general retailers and registered pharmacies where these exist. Outlets such as bars, 
hardware shops and salons are excluded. Retail outlets will be identified initially from lists 
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provided by PSI. This will be supplemented by visiting the areas and confirming the list with 
local leaders. In addition, a snowballing technique will be used where shopkeepers of known 
retail outlets will be asked to identify other retailers within the local area. All identified retail 
outlets being regularly accessed by the populations within the selected control and intervention 
sub locations will then be mapped. Field workers will visit each retail outlet and position it using 
a Global Positioning System (GPS) unit (Garmin etrex (Garmin Ltd, Kansas, USA) and Trimble 
12 band). Three longitudinal and latitudinal readings will be taken for each outlet and the 
average reading noted to minimise errors in positioning. Current estimates indicate that the 
accuracy of GPS readings is within 15 meters of the true position [63]. Details of the type of 
anti-malarial medicines stocked within each outlet will also be recorded.  
 
The database derived from these analyses will form the sampling frame for other retail outlet 
surveys and will also be used to monitor any leakage of public sector AL into retail outlets, any 
stocking of project AL by untrained private retail outlets, to monitor the coverage of the 
intervention and the distance of retail outlets to neighbouring households, hence accessibility. 
The following indicators will therefore be monitored from this survey: 
 
A. The proportion of sub-locations with at least one AL source 
 
B. Availability of public sector AL in private retail outlets 
 
C. Availability of private sector project AL in untrained private retail outlets 
 
D. The proportion of retailers stocking project AL at follow up survey 
 
The retail census will take place before other baseline data collection activities and will be 
updated before the follow up data collection activities both in the control and intervention areas. 
Data will be collected on retail census questionnaires. It is estimated that the census will cover a 
maximum of 49 retail outlets per sub location; 882 retail outlets in total (Table 5). Verbal 
consent to collect these data will be obtained from the available shopkeeper in each retail outlet. 
 
2) Household Survey  
 
The indicators to be measured include: 
 
A. The proportion of children under 5 years with fever in the past 2 weeks who started 
treatment with AL within 24 and 48 hours of fever onset, overall, by socio-economic 
group (SEG) and treatment source 
 
B. The proportion of children under 5 years with fever taking AL who adhered to the 
treatment dose, by source 
 
C. The proportion of under 5 years with fever who took an anti-malarial monotherapy in the 
past 2 weeks 
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D. The proportion of children under 5 years with fever in the past 2 weeks who sought 
treatment by source (e.g. public, mission & commercial health facilities, pharmacies, 
other retail outlets, Community Owned Resource Persons (CORPs), traditional healers 
and other sources) 
 
E. The proportion of non-target household members receiving intervention AL to treat a 
fever within the past two weeks
5
 
 
F. Household cost of fever episode (for all completed episodes) 
 
G. The proportion of households within 30 minutes and within 1 hour travel time from an 
AL source 
 
H. The proportion of caregivers with knowledge of malaria symptoms, danger signs, AL and 
correct AL dose for a 4 year old 
 
These indicators aim to monitor any changes in access to effective anti-malarial treatment, 
adherence, treatment seeking behaviour and knowledge of malaria within the households. 
Indicators B, C and H will also be important as factors which potentially affect the development 
of resistance. 
 
The household survey will be carried out both at baseline and post intervention, within the 
intervention and control sub-locations. Three enumeration areas (EAs) will be selected per sub-
location (with probability proportional to size of EA). We will randomly sample 20 homesteads 
within each EA, equivalent to a total of 540 homesteads (roughly 1922 households) in each 
group. We will aim to visit the same 20 homesteads in the follow-up as in the baseline to 
optimise statistical power. Where it is not possible to visit the same homestead we will replace it 
with its nearest non-sampled neighbour. The sampling frame of homesteads in each EA will be 
created with the help of local village leaders. The list will be confirmed by visiting the EAs a 
month before the field work commences and recording GPS co-ordinates for each identified HH.  
 
A household survey questionnaire will be administered to the household head and all care givers 
of children under 5, filling in one questionnaire per child. All indicators apart from indicator E 
will be focused on children under five years since they are the most vulnerable group. To 
monitor ‘the proportion of non targeted household members receiving the intervention AL’ 
(indicator E), a brief additional questionnaire will be administered to all members of the 
household aged 5 or over who had a fever within the past 2 weeks (care givers will be 
interviewed on behalf of children aged 5-15), to estimate what treatment was used and from 
which source. Indicator D will provide information on the leakage of project AL to untrained 
outlets. This will augment data collected for indicator C in the retail census i.e. ‘availability of 
private sector project AL in untrained private retail outlets’.  
 
                                                          
5
 As the pack sizes cover children aged 6 months to 3 years and 4 to 8 years, we will assess the proportion of people 
aged 9 years and over who obtained intervention AL. In addition, as the main target group for the interveniton is 
under fives, we will assess the proportion of people aged 5 years and over who obtained intervention AL.  
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The survey is restricted to fevers occurring in the previous two weeks since the recall period 
beyond this time point is questionable [64]. Although the RBM indicator states that treatment 
should be sought within 24 hours, 48 hours has also been included in indicators A and B as this 
could still be considered prompt. The denominator for 24 and 48 hours in these indicators 
includes all individuals reporting fever and visited by interviewers 2 to 3 days or more after the 
onset of symptoms. As the intervention aims that all under 1s should be referred to a health 
facility, and should not therefore receive AL from retailers except in an emergency, Indicator A 
will be calculated both with and without this group in the numerator. For indicator B, adherence 
will be defined as taking the quantity of medicine specified in the MOH treatment guidelines, 
and both under and over dosing will be considered as non-adherence. The timing of 
administration between doses within the 3 days will not be considered as recall of specific times 
may prove difficult.  A photo-illustrated guide will be used to aid in the identification of anti-
malarial treatments [25, 64]. 
 
Wealth indicators based on those used by the Demographic and Health Surveys (DHS) will be 
collected this survey to determine the socio-economic status of each household and gain better 
information on the equity impact of the intervention [65, 66].Wealth indicators will include 
housing quality, sources of income, education status and ownership of livestock of the household 
head. Principal components analysis (PCA) will be used to construct a household wealth asset 
index from the information collected. The derived wealth indices will then be used to classify 
households into wealth quintiles [67].  In addition households can be linked to national socio-
economic quintiles using asset weights from nationwide surveys. Wealth indicators will be 
collected during both baseline and follow-up household surveys since they are subject to 
variation [67]. GPS co-ordinates will also be taken for each household interviewed to determine 
the distance of the household to the nearest retail outlet and facility. 
 
Written consent will be obtained from the household head or their representative and verbal 
consent from the interviewee. The village elder or chief will be informed about the survey in 
advance. The village elder will be asked to aid the field team in identifying the households to be 
interviewed within the designated enumeration areas. 
 
Sample Size Determination for Household Survey 
 
The sample size calculation is based on a cluster randomized before and after study design, with 
9 intervention and 9 control sub locations stratified across the three districts (Busia, Teso, 
Butere/ Mumias). The key outcome indicator is indicator A: The proportion of children under 5 
years with fever in the past 2 weeks who started treatment with AL within 24 and 48 hours of 
fever onset, overall, by SEG and treatment source. The study design chosen for this study is a 
cluster randomised sample, for logistical reasons. The cluster randomisation will occur at the EA 
level with the primary sampling unit being the household.  
 
Using a ‘difference in proportion’ sample size calculation and an estimated design effect  
the following was calculated (Appendix 3):  
 
To detect a difference of 20 percentage points in the key outcome indicator, with a 5% 
significance and 80% power:  
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n = [(zalpha/2 + zbeta)
2
(p1 (1-p1) + p2(1-p2)] / (p1 - p2)
2 
 
Where: 
 
n = desired sample size (recent childhood fevers) in each group 
 
zalpha/2 = 1.96 (5% significance) 
 
zbeta =  0.84 (80% power)  
 
p1 (control) = 0.2, the starting percentage (data derived from a fever survey carried out in June 
2007 showed 11% of children under the age of five had access to an anti-malarial within 48 
hours. This was increased to 20% to be conservative as a larger p1 will require a larger sample 
size). 
 
p2 (intervention) = 0.4, the starting percentage plus a 20% point increase (assuming that a 20% 
point increase is the minimum necessary to justify the importance of the intervention in public 
health policy terms). 
 
n = 79 childhood fevers required in each group (i.e. control and intervention arms) 
 
Based on previous surveys carried out in Kisii, Kwale and Bondo [27, 60], 3.4 homesteads (HS) 
need to be visited to find one recent childhood fever. Therefore a total of 269 HS will be required 
in each group.  
 
Assuming a design effect of 2 to allow for clustering, a total of 538 HS will be required in each 
group, equivalent to 60 HS per sub-location (or around 214 households per sub-location [27, 
60]). If 20 HS were surveyed per EA, we would need to evaluate 3 EAs per sub-location. This 
would equate to a total of 27 EAs in the intervention group and 27 in the comparison
6
. This will 
be feasible for the majority of EAs, as data from Kisii, Kwale and Bondo show that the number 
of HS per EA ranges from 3-110 (mean=36, inter quartile range= 23-41). Where EAs with less 
than 20 HS are selected, they will be replaced with the nearest EA with at least 20 HS (Table 5). 
 
In addition, sample size calculations estimates were also made using the Hayes and Bennett 
Cluster Sampling Formula IJE 1999 
7
 (Appendix 2), which also showed that 27 EAs in each 
group would be adequate as a sampling frame. 
 
                                                          
6
 If the design effect is increased to 3, 45 EAs will need to be evaluated in the intervention group and 45 in the 
control group. 
7 Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. International Journal of 
Epidemiology, Vol 28, 319-326. 
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3) Provider Survey  
 
The indicators to be measured include: 
  
A. The median price charged by retail outlets for AL by age band 
 
B. The proportion of retail outlets with no expired AL available in stock 
 
C. The proportion of retail outlets reporting stock outs of AL within the past 2 weeks 
 
D. The proportion of retail outlets storing AL appropriately (see definition of ‘appropriately’ 
below) 
 
E. The proportion of retail outlets that have copies of the materials/ job aids required by the 
intervention (e.g. leaflets, posters, guidelines, pharmacovigilance reporting forms) 
 
F. The proportion of retail outlet staff who know the correct information about malaria 
diagnosis and treatment practices 
 
These indicators aim to monitor the affordability of anti-malarial therapies within the retail 
sector, whether any subsidies are passed onto the consumer and the nature of retail supplies of 
anti-malarials and source. In indicator C, the period of monitoring stock outs i.e. two weeks is 
chosen for recall purposes. In indicator D, ‘appropriate’ storage refers to keeping medicines off 
the floor, in a dry area, away from direct sunlight, and with the packaging intact. Also included 
in this survey will be questions to assess the knowledge of the provider including what he/ she 
knows about malaria symptoms, diagnosis, treatment and ADRs.  
 
The indicators will be assessed through a provider survey questionnaire.  Questions will be asked 
to the retailer present at the shop. Verbal consent to administer this questionnaire will be sought 
from the interviewees.  
 
Sample Size for the Provider Survey: The survey will be conducted in outlets selected to 
deliver the subsidised ACT product. Depending on the total number of outlets included in the 
intervention, we may include all outlets in the provider survey, or take a random sample. It is 
estimated that around 150 outlets will be surveyed in each group (i.e. control and intervention 
groups (Table 5). 
 
4) Mystery Shopper Survey 
 
The indicators to be measured include: 
 
A. The proportion of retail outlet staff that dispense AL to patients presenting with fever 
 
B. The proportion of retail outlet staff that dispense the correct dose of AL to patients 
presenting with fever  
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C. The proportion of retail outlets that provide appropriate information to caregivers on how 
to give/ take AL 
 
D. The proportion of encounters where retail outlet staff asked  for one or more IMCI danger 
signs to determine need for referral 
 
E. The proportion of retail outlet staff who told caregivers about any signs of progressive 
illness and recommended a referral visit to a facility or clinic if the signs appear 
 
F. The median price charged for an AL dose by age group 
 
The aim of this survey is to analyze the patient provider interaction to give better information on 
actual rather than self-reported provider behaviour. This survey will take place before the 
provider survey to avoid making retailers aware that they are being evaluated. It will augment 
and allow for triangulation with the provider survey.  
 
The survey will take the form of a mystery shopper survey. Here, field workers will pose as 
ordinary care givers seeking care for a four year old child with fever. Questions will be 
administered  to the staff selling medicines at that time, and any recommended medicines will be 
purchased by the field worker. Details of the interview will be filled in away from the outlet. 
Questions will be standardized between retail outlets to allow for comparisons of behaviour 
between retailers and over time. The indicators and data collection tools for this activity will be 
further refined once a detailed outline of the intervention activities have been developed. This 
method was chosen instead of direct observation or exit interviews because it minimises any 
potential bias that may occur through knowing one is being observed. In addition, achieving a 
reasonable sample size for exit interviews could be very time consuming in outlets which receive 
very few fever customers per day. This technique does however raise some ethical concerns as 
informed consent cannot be obtained from the medicine seller at the time of the interview [68-
70]. Verbal consent will therefore be sought from all shopkeepers during the retail census for 
their willingness in principle to participate in the mystery shopper survey. They will be informed 
on what the survey involves, however neither whether their shop will be selected for the survey 
nor the date of the visitation will be revealed as this may affect the study outcomes.  
 
Sample Size for Mystery Shopper Survey: The mystery shopper survey will be conducted in 
the same outlets as the provider survey (Table 5). 
 
 
5) Focus Group Discussions (FGDs) 
 
Focus Group Discussions will be carried out only after the implementation of the intervention 
and only within the intervention sub locations. The purpose is to ascertain the perceptions and 
opinions of the intervention from community members and shopkeepers. This may help confirm 
and explain observations in the quantitative data. Each group will contain 6 to 10 people. Two 
FGDs will take place per intervention sub location (i.e. a total of 18 FGDs, see Table 5). In each 
sub location a group of selected shopkeepers and a group of selected caregivers of children under 
five will be interviewed separately. To ensure that a range of experiences are presented, 
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shopkeepers will be selected purposively, based on data from the provider survey to ensure that 
they include a mixture of those considered to be well and poorly performing. Care givers will be 
purposively selected based on treatment seeking behaviours, as revealed from the household 
survey.  
 
Discussions will take the form of semi-structured interviews. Shopkeepers will be asked about 
the benefits and costs of being involved in the program as well as problems they may have 
experienced in the implementation process. Care givers will be asked about their opinions on 
treatment sources, availability of products, barriers faced in seeking treatment and any concerns 
they may have regarding the program. In addition the use of intervention AL in adults will also 
be explored (drug misuse).  
 
A letter of invitation to the FGD sessions will be presented to the care-giver, his/ her household 
head and to the shopkeepers to be interviewed. It will explain the duration of the interview and 
that they may need to arrange for someone to carry out their daily activities for that period of 
time. A travel allowance will be given to each interviewee and drinks will be provided during the 
sessions. Verbal consent to carry out these discussions will be gained from the interviewees prior 
to initiation of the discussions. Discussions will be tape recorded and records supplemented by 
notes taken during the discussions by a field assistant. This will ensure the capture of verbal and 
non verbal cues and facilitate exploration of arising issues.  
 
6) Documentation of Context 
 
We will undertake careful documentation of context at national and district level and other 
factors which may have influenced the study outcomes in both the intervention and control areas. 
A list of issues that may be of concern will be prepared to provide a framework for data 
collections. Throughout the study, a series of desk-work analyses of newspaper articles, minutes 
to meetings, draft proposals, budget allocations and memos, as well as in-depth discussions with 
the District Health Management Teams (DHMTS) at the local level, the DOMC at the national 
level and other relevant bodies will take place. From this, a chronology of events will be 
documented, as well as a summary of the events, the locations and the duration. These data will 
be taken into consideration during evaluation of the study outcomes.  
 
Table 5: Summary of Sample Sizes Required for each Data Collection Activity 
 
DATA COLLECTION ACTIVITY UNIT OF ANALYSIS NUMBER 
PER SUB 
LOCATION 
TOTAL 
NUMBER OF 
SUB 
LOCATIONS 
TOTAL 
SAMPLE 
SIZE IN ALL 
SUB 
LOCATIONS 
RETAIL CENSUS Retail outlet 49 18 882 
HOUSEHOLD SURVEY Homestead (household) 60  (214 ) 18 1080 (3845) 
PROVIDER SURVEY Retail outlet 17 18 306 
MYSTERY SHOPPER Retail outlet 17 18 306 
FOCUS GROUP DISCUSSIONS Shop keeper groups of 6-10 1 9 9 
FOCUS GROUP DISCUSSIONS Care giver groups of 6-10 1 9 9 
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Estimating the Cost and Cost-effectiveness of the Intervention 
 
Cost and cost-effectiveness data is considered important by the DOMC for assessing the 
affordability and value for money of all potential interventions. However, it is recognised that the 
unit costs of small scale pilots will not reflect those of nation-wide implementation, as they 
exclude certain activities (e.g. mass media) and do not reflect economies of scale. KWTRP will 
not therefore conduct a detailed costing of the pilot. However, the DOMC have decided to 
employ a costing consultant who will work together with PSI and other implementing agencies 
to provide comparable estimates of the costs of future nation-wide interventions. The indicators 
to be measured include: 
 
A. Implementation cost 
 
B. The cost-effectiveness in terms of the incremental cost per additional child receiving 
prompt AL treatment 
 
For the cost-effectiveness indicator, the ‘effectiveness’ measure will be obtained from the 
household survey. Potential differences in effectiveness between pilot and nation-wide 
implementation will be assessed using sensitivity analysis.  
 
Feasibility of the Pilot in the Current Political Situation 
 
In view of the current post election violence, certain measures will be undertaken to ensure the 
safety of the research study team: 
 
 The security and acceptability of the survey work will be discussed at length with local 
district ministry staff, police, community elders and KEMRI management before travelling to 
the field.  
 Recruitment of local staff will be sensitive to the ethnic tensions within the selected 
communities that will be surveyed.  
 
ii) Provisions for data verification, and validation in the field  
 
Field workers selected to administer the questionnaires will be chosen according to their level of 
field experience. They will be fluent in the local dialects spoken in the chosen districts. They will 
translate the tools into the local language then back translate them to ensure the questions have 
been translated correctly. Field workers will also undergo two days of training before baseline 
and intervention surveys to educate them on the purpose of the study, how to fill in the 
questionnaires and the quality of work expected from them. 
 
As previously mentioned, the data collection tools (both qualitative and quantitative) have drawn 
on previous similar surveys [60, 62, 71], with results which have been published in peer 
reviewed journals. They have been adapted to suit the purposes of this study and will all be 
piloted prior to the surveys and further adjusted, if necessary. Data collected from the different 
tools can be compared to validate responses from different sources. 
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During the surveys, questionnaires will be reviewed at the end of each day by the team leaders to 
ensure all entries are completed appropriately. Any tools with incomplete or questionable entries 
will be sent back to be re-filled the next day. In 10% of the interviews in the retail census, the 
household survey and provider survey, field workers will be accompanied by the team leader to 
monitor their performance and see where any improvements can be made. Also, a random 
sample of 5% of interviewees in each area will be re-interviewed by team leaders (back-
checking) to ensure concordance in responses. The focus group discussions will take place with 
the principal investigator (BB Kangwana) and an interpreter. 
 
9) Data Management 
 
9a) Data Storage 
 
All data collected from the surveys will be cleaned before and after data entry and will be stored 
on PCs and USB drives at the KWTRP unit in Nairobi. All data on computers will be secured 
through the use of passwords. Tapes from the qualitative analyses, field notes and hard copies of 
the questionnaires will be stored in locked filing cabinets on site. All data entered into software 
will only have individual identification numbers. Access to any of these materials will be limited 
to investigators and when necessary clerks for data entry purposes.  
 
9b) Data Management/ Data Analysis 
 
Quantitative Data: Data collected from the retail census, household survey, provider and 
mystery shopper tools will be entered into individual customized data entry screens on MySQL 
(Version 5.1, California). These screens will be designed to be as similar as possible to the hard 
copies with consistency checks and built in ranges. Data will be double entered into the system 
by two different clerks. Microsoft Excel 2007 and STATA (version 9 StataCorp, College Station, 
Texas) will be used to analyse these data.  To account for the different sampling weights of the 
EAs in the districts selected, estimates of proportions and means will be calculated using 
STATA’s ‘svy’ commands. A wealth indicator will be calculated using PCA of household assets. 
From this, quintile distribution will be derived [67].  
 
Qualitative Data: Data collected from the focus group discussions will be entered and 
transcribed in NVivo 7.0 software (QSR International). This software will allow data to be coded 
systematically into themes and sub-themes that can be evaluated to highlight the perspectives of 
households and retailers on the retail intervention package.  
 
 
10) Time Frame  
 
 2008 2009 
 
2010 
 M-A M-J J-A S-O N-D J-F M-A M-J J-A S-O N-D J-F M-A 
KWTRP  tool pilots 
 
              
Retail census 
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Baseline Data Collection 
 
             
Data entry, coding and 
cleaning 
             
PSI AL intervention
+
 
 
             
Retail census updated 
 
             
Post Intervention data 
collection 
             
Data entry, coding and 
cleaning 
             
Focus Group Discussions 
 
              
Analysis of quantitative and 
qualitative data 
              
Report and dissemination 
meetings 
             
 
+ See appendix 5 for a detailed timeline of the PSI, AL intervention. 
 
11) Ethical Consideration 
 
This pilot was designed to provide the DOMC and MOH with the evidence they require to 
inform the decision on whether AL should be rolled out into the private retail sector, and how. 
The DOMC participated and approved in designing a list of key indicators which they feel are 
important for their decision making process.  The key indicators also incorporate DOMC targets. 
All information collected from this study will be fed back to the DOMC to inform policy.  
 
Community Engagement: Prior to baseline and post-intervention surveys, letters will be sent to 
the relevant DHMTs and District Officers (DOs). These letters will explain the study and its 
purpose. On arrival, the field team leader will meet with both parties, present a copy of the letter 
and verbally discuss the planned field work. During these discussions concerns or queries about 
the survey may be voiced. Once approval has been gained a representative from the DHMT will 
escort the team leader to the relevant village elders, chiefs and/ or local leaders. They will be 
given a copy of the letter given to the DHMTs together with a verbal explanation. Queries and 
concerns will be addressed during this time and verbal approval will be sought to go ahead with 
the survey. The DHMTs, DOs and community leaders will have access to the team throughout 
the survey so any concerns that arise during the survey can be addressed to the field team leader. 
 
Individual consent: During the surveys, consent will be obtained from the necessary 
individuals. Informed sheets and consent forms will be translated into the local dialect. A copy of 
the information sheet will be left for the household heads and shopkeepers. The information 
sheet will include an introduction, the purpose of the study, how questions will be administered, 
the risks and benefits to those who participate, that the data collected will be confidential and 
that participation is purely on a voluntary basis. Written or verbal consent will be obtained prior 
to baseline and intervention surveys. All verbal consent will be witnessed by a study team 
member. For the household survey written consent will be gained from the household head or 
his/ her representative and verbal consent from all other interviewees. For the retail census and 
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provider surveys verbal consent will be obtained from the interviewees; for the focus group 
discussions, verbal consent will be obtained from the caregivers and from the shopkeepers. 
Verbal consent for the mystery shopper survey will be obtained from the shopkeepers during the 
retail census survey. In all surveys interviewing shopkeepers, verbal as oppose to written consent 
will be obtained since previous experience shows that shopkeepers tend to be very cautious of 
inspectors and suspicious of having to sign documents that may be used to identify them or their 
shop. 
 
Participants will be able to drop out at anytime within or between surveys and do not have to 
respond to questions they do not wish to. However, reasons for not participating or not 
answering questions will be obtained as this may be due to aspects of the surveys or intervention 
that are not acceptable to the community and that will therefore need to be acknowledged and 
possibly altered. Great efforts will be made to ensure that participant’s confidentiality will be 
maintained at all times. This includes restricting access of all data to the investigators and data 
entry clerks when need be, destroying of tapes from FGDs after the research is completed, as well as 
using individual identification numbers on software programs for data analysis. 
 
Training for those involved in administering consent: All fieldworkers will undergo training 
prior to both studies. Training will educate fieldworkers on the purpose of the study, the 
importance of consent and how to administer both the consent forms and questionnaires.  While 
in the field, fieldworkers will have daily contact where possible through the use of a mobile 
phone with the team leaders and KWTRP headquarters in case of any queries. 
 
One potential concern is that AL will be temporarily de-regulated in the study location from a 
POM to an over the counter medicine (OTC). AL has been used in public facilities for one year, 
however very little evidence from wide scale distribution is available on the range and impact of 
adverse effects of AL as an OTC medicine. The use of AL in this study will only be allowed 
after approval from the PPB. Retailers will be trained on when to refer patients to the public 
health sector; this information will also be printed on the pre-packaged AL leaflets. 
 
The control areas will not have access to AL as an OTC medicine however, the government will 
continue providing it free of charge within the public sector in all districts. Therefore the existing 
access to AL in the control group will not be adversely affected.  
 
During this pilot, retail sector AL will be heavily subsidized within the intervention group which 
could raise questions on sustainability. If, from all the available evidence the DOMC are willing 
to distribute AL within the community then there is a high possibility that funds to subsidise this 
medication at this level/ scale will become available through the implementation of Global 
Subsidy Funding for ACTs [72]. 
 
Feedback of information: Please refer to item 12: expected application of results.  
 
11 b) Animal Subjects: Not applicable 
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12) Expected Application of Results 
 
The results from this study will be fed back to the DOMC, DHMTs in the study sites, and other 
interested stakeholders. This will occur together with other studies taking place within and 
beyond Kenya on retail sector ACT delivery and other strategies to improve access. This pilot 
will form part of the evidence required by the DOMC to inform the decision on whether 
distributing AL through the private retail sector will increase prompt access of effective anti-
malarial treatment to those who may benefit from it. The evidence may also be useful to other 
countries thinking of rolling out similar interventions and to national and international 
organizations who may be willing to fund such interventions at a national level.  
 
The findings will be communicated to relevant and interested stakeholders through written full 
reports, summary briefing notes, group discussions and one on one meetings, published papers 
and presentations at international conferences.  
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 14) Budget 
 
Item Amount(US$) Amount (Kshs) 
a) Personnel salaries and benefits 151,054 9,969,564 
b) Patient Costs NA NA 
c) Equipment NA NA 
d) Supplies 3,840 253,440 
e) Travel and accommodation 14,800 976,800 
f) Transportation NA NA 
g) Operating expenses 196,305 12,956,130 
h) Animals NA NA 
i) Consultancy fees NA NA 
j) Contingency funds NA NA 
k) Institutional administrative overheads 45,784 3,021,744 
Total 411,783 27,177,678 
 
15) Justification of Budget 
 
This budget only covers the cost for the evaluation of the pilot. All intervention costs will be 
estimated and finance sort by PSI.  
 
Personal Salaries and Benefits: The principal investigator, (BB Kangwana) and an assistant 
research officer will be paid for a period of 24 months. The role of the assistant research officer 
will be to monitor the progress of the surveys in the field. Salaries for the research assistant and 
assistant research officer have been calculated using the appropriate KWTRP salary scales. 
Salaries also include 8 months for Catherine Goodman who will provide the majority of 
supervisory support. She will be paid according to the London School of Hygiene and Tropical 
Medicine salary scale. 
 
Operating Expenses: This includes all costs required to carry out the field studies. The retail 
census, household survey, provider survey and mystery shopper survey will be carried out twice 
over a period of two years, at baseline and post intervention. The focus group discussions will 
only be carried out post intervention while documentation of context will be collected throughout 
the study period. The operating costs include travel costs, per diems and salaries of the field 
workers as per KWTRP guidelines. Training days will be held before each survey, one for the 
team leaders, one for the field workers on data collection, and one for all staff on the use of GPS 
units to map households and shops. Salaries and transportation costs will need to be paid to those 
attending the training days.  Once in the field, village elders will be asked to help in locating the 
households and shops and will be paid 100ksh per day. The salaries and per diems are included 
for one field worker and a team leader to remain in the field for an extra three days after the 
surveys are complete to deal with any remaining errors that need to be corrected (call backs). 
Also included are costs for the production of the questionnaires, costs to pilot the questionnaires, 
the salaries for a software developer to design the data entry screens and clerks for data entry 
purposes and the costs to purchase 11 GPS units. 
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Supplies: This is the estimated cost of all the non-field work supplies required for the study at 
the KWTRP unit in Nairobi. It includes photocopying, stationary, communication and printing 
over the two year period. The estimates are based on routine costs charged at the KWTRP. 
 
Travel and Accommodation: During the protocol development and study preparation an 
investigator will need to meet with a statistician and retail sector consultants in Kilifi. Travel and 
accommodation costs for these trips have been factored in here. Again, while the surveys are 
going on, an investigator will need to travel to the field sites for a couple of days to monitor the 
progress on the ground, check the quality of the data collection and deal with any major issues 
that may present. All costs for travel and accommodation have been estimated using standard 
KWTRP mileage and per diem charges.   
 
16) Appendices 
16a) Role of Each Investigator 
 
Miss BB Kangwana: PI- Will be responsible for proposal development, supervision of training, 
data collection, analysis and report preparation and communication. 
 
Dr C Goodman: Will play a supervisory role in designing and co-ordinating proposal 
development and provide scientific guidance for the study. 
 
Dr G Fegan: Will provide statistical support in study design and analysis. 
 
Dr AM Noor: Will be involved in developing GIS platforms and evaluation of socio-economic 
status. 
 
Dr AJ Nyandigisi: Program pharmacist, Division of Malaria Control. Will be the principal 
representative/ liaison person for the DOMC. Will be responsible for coordinating planned 
HMM pilots for DOMC purposes and, in informing policy discussions on issues raised in the 
protocol and subsequent publications arising from the protocol. 
 
Dr WS Akhwale: Head of Division of Malaria Control, Ministry of Health; will be responsible 
for informing policy discussions on issues raised in the protocol and subsequent publications 
arising from the protocol. 
 
Pharmacy and Poisons Board: Will act as an advisory body on pharmaceutical issues in the 
study, responsible for informing policy decisions on issues raised in the protocol and subsequent 
publications arising from the protocol. The PPB will also be responsible for the monitoring and 
evaluation of ADRs. This includes working with PSI and the DOMC in distribution of referral 
forms, training of shop keepers and health care workers on how to identify and record ADRs, 
and collection and analysis of data from referral forms and any other tools used to record ADRs..  
 
Dr Jayesh Pandit: Head of Pharmacovigilance, Pharmacy and Poisons Board, Ministry of 
Health; will be the principal representative/ liaison for the PPB, co-ordinating communications 
between the PPB and other participatory bodies.  
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Prof RW Snow: Responsible for overall scientific guidance for the study, its interpretation and 
write up.  
 
16b) Attached relevant documents
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APPENDIX 1 
 
CVs of non-KEMRI investigators 
 
Name: Willis Akhwale 
Position: Head, Division of Malaria Control, Ministry of Health, Nairobi, Kenya. 
Education: 
 University of Nairobi, College of Health Sciences, Bachelor of medicine and surgery 
(MbChB),1991. 
 Aga-Khan, Nairobi, Diploma in Primary Health Care, 1996 
 Tokyo Women`s Medical University, Tokyo, Japan, PhD in Tropical Medicine, 2000. 
Previous Positions: 
1991-1992 Rift Valley Provincial General Hospital, Nakuru, Kenya, internship in medicine,  
paediatrics, surgery, obstetrics and gynaecology. 
1992-1993 Medical officer in the surgery department, Rift Valley Provincial General Hospital  
Nakuru. 
1993-2000 District Medical Officer of Health, Trans Nzoia district. 
Publications: 
 Fegan GW, Noor AM, Akhwale WS, Cousens S & Snow RW (2007). Effect of expanded 
insecticide-treated bednet coverage on child survival in rural Kenya: a longitudinal study. 
Lancet, 370:1035-9. 
 Noor AM, Amin AA, Akhwale WS & Snow RW (2007). Increasing coverage and 
decreasing inequity in insecticide-treated bed net use among rural Kenyan children. PLoS 
Medicine, 4:e255. 
 Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS & Snow 
RW (2007). The challenges of changing national malaria drug policy to artemisinin-based 
combinations in Kenya. Malaria Journal, 6:72. 
 Zurovac D, Larson BA, Akhwale WS & Snow RW (2006).The financial and clinical 
implications of adult malaria diagnosis using microscopy in Kenya. Tropical Medicine 
and International Health, 11:1185-94. 
 Akhwale WS, Lum JK, Kaneko A, Eto H, Obonyo C, Bjorkman A & Kobayakawa T. 
(2004). Anaemia and unstable malaria at different altitudes in Kisii District of the 
highlands of western Kenya. Acta Tropica, 91:167-7 
 
Name:  Andrew J. Nyandigisi 
Position : Program Pharmacist Division of Malaria Control in charge of community access of 
antimalarials, pharmacovigilance and QA/QC of anti-malarials . 
Education   
 University of Nairobi, College of Health Sciences, Bachelor of Pharmacy 2004 
 Training on overview of Supply Chain Management for Commodity Security by JSI 
deliver (Johannesburg) 
 Training on Minilabs for QC of anti-malarials by USP (Addis Ababa) 
Previous positions  
 Hospital Pharmacist Kenyatta National Hospital 
 Internship in Community pharmacy Lemuma Pharmacy 
 Internship in Industrial Pharmacy ELYS chemical industries 
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APPENDIX 2 
 
Household Survey Sample Size Calculation Using Hayes and Bennett Cluster Sampling 
Formula IJE 1999 
8
 
 
An alternative way to calculate sample size is by using the Hayes and Bennett Cluster Sampling 
formula:  
 
c = 2 + 7.84 [p1 (1-p1)/n + p2 (1-p2)/n + k
2
(p1
2
 + p2
2
)] / (p1 - p2)
2 
 
(Eq 4 adjusted for matching by adding 2) 
 
Where 
 
c = number of clusters 
 
n = Average expected number of fevers per cluster  
 
k = co-efficient of variation, estimated at 0.25, based on figures used by Hayes and Bennett 
 n = (20 HS per EA)  * (no. of fevers per HS)   = 5 (rounded down) 
 c = 21 EAs in intervention group and 21 in control group 
 i.e. 2.4 EAs per division. 
If increased k to 0.35 would require 23 EAs in each group and therefore 2.6 EAs per sub 
location.  
 
This implies that the 3 EAs per sub location estimated in approach a) above can be considered 
adequate.  
                                                          
8 Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. International Journal of 
Epidemiology, Vol 28, 319-326. 
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APPENDIX 3
Sample Size Calculation for ACT Retail Study             
         Parameters                 
z_alpha/2 1.96 standard 
      z_beta 0.84 standard 
      p_control 0.2 Fever survey June 07 gave 11% but increased to be conservative (proportion with access to AM within 48 hours) 
p_intervention 0.4 Assuming a 20% point increase after intervention 
  No. HS to get one fever 3.4 average across survey data (exc. Makueni) 
   Design effect 2 estimate 
      Sub-locations per group 9 study design 
     
k 0.25 
estimate used in Hayes & Bennett - based on 2001/2 survey data we had calculated 0.16 so 0.2 could be considered 
conservative 
number of HS sampled per cluster 20 chosen based on being about to find at least 20 HS in most EA as IQR is 23-41  
number of fevers per cluster 5 
       
         
         Calculation based on individual randomised study plus design effect         
n 79 fevers in each group 
     No. HS 269 
       No. HS + design effect 538 
       No. HS per sub-location 60 
       EA sampled per sub-location 3 
       EA per intervention group 27 
       
         
         Calculation based on cluster randomised study using Hayes & Bennett equation 4, adjusted for matching   
c, number of clusters 21.00 
       EA per sub-location 2.4 
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APPENDIX 4 
 
Key Indicators for Evaluating Interventions to Expand ACT Coverage in Kenya 
 
Background 
Kenya has been delivering artemisinin combination therapy (ACT) through the public sector since mid-
2006. Early evaluations show this led to an increase in the percentage of children under 5 receiving 
antimalarials from 14% to 26% within 48 hours, of whom 30% received artemether- lumefantrine (AL) 
(KEMRI/Wellcome Trust, 2007). However, access remains well below the Roll Back Malaria target of 
60%, with the majority of patients still failing to receive prompt effective treatment. The Ministry of 
Health (MOH) is committed to exploring alternative delivery channels that can complement existing 
facility-level delivery, and thus improve community access to ACT. These could include delivery through 
drug retailers, Sustainable Health Enterprise Foundation (SHEF) clinics, Community Owned Resource 
Persons (CORPs) or other volunteers. Pilots of such interventions have been proposed by a number of 
groups, and the Pharmacy and Poisons Board (PPB) is expected to approve a special dispensation to 
allow over the counter (OTC) status for AL for these pilots. 
The Division of Malaria Control (DOMC) is keen to ensure that evidence arising from these pilots is of 
high quality and based on common indicators, to facilitate comparison of results and identification of 
policy implications. This paper therefore outlines core indicators which should be included in all studies, 
and identifies optional complementary indicators which may also be included. In addition, each pilot 
may wish to add their own indicators that address outcomes specific to their interventions or interests.  
The indicators have been identified through consideration of DOMC targets, Global Fund (GF) and Roll 
Back Malaria Monitoring and Evaluation Reference Group (RBM MERG M&E) frameworks, and the draft 
monitoring and evaluation (M&E) guidelines for the global ACT subsidy. 
 
Guidelines on Study Design 
All studies must include either: 
 Pre and post intervention data 
 Intervention and control groups 
It is strongly recommended that both are included (i.e. pre and post for intervention and control 
groups). However, this may be infeasible for some studies, for example where the intervention has 
already begun, or where no appropriate control groups exist.  
Cluster randomization of outlets to intervention and control groups reduces the potential for bias. 
However, it may be infeasible for some interventions which need to function at a certain minimum 
scale, or where “contamination” would be likely between clusters (e.g. residents from control clusters 
could visit outlets in intervention clusters or receive communication messages targeted at the 
intervention group). In most cases it is therefore likely that there may be only 1 or 2 control and 
intervention areas. 
 
Study Indicators 
Indicators have been divided into 3 groups: 
A. Indicators to be included in all studies (please refer to back page for summary) 
B. Optional complementary indicators 
C. Indicators likely to be beyond the scope of pilot studies 
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A. Indicators to be Included in all Studies 
A1: Household Survey Indicators 
Indicator 1: The proportion of children under 5 years with fever in the past 2 weeks who started 
treatment with a first line ACT within 24 and 48 hours of fever onset, overall, by socio-economic group 
(SEG) and treatment source  
 This will be the primary indicator for all studies. It is a standard RBM indicator collected as part 
of the Multiple Indicator Custer Surveys (MICS) and the Demographic and Health Surveys (DHS) 
and a core GF indicator. 
 It requires collection through a household survey, which will represent an additional expense for 
some pilots. However, it is essential in order to measure the overall impact on ACT coverage 
from both facility and non-facility sources. This is important as an intervention with high levels 
of ACT provision through non-facility sources would not be considered a success if it reduced 
facility provision, and possibly even reduced ACT coverage overall. 
 All compulsory household survey indicators focus on children under 5 years as the most 
biologically vulnerable group. Older groups are also important, but their inclusion would 
increase the complexity of the household survey. The same indicators for these groups are 
therefore considered optional. 
 2 weeks is the standard recall period for this indicator. 
 We focus on fever (rather than malaria) as the majority of febrile illnesses do not receive 
parasitological confirmation, and fever is the main symptom used in clinical diagnosis. In 
addition, for most communities in Africa, fever is the prompt for seeking treatment. 
 We have included both 24 and 48 hours (although RBM targets have been specified in terms of 
24 hours), as treatment within 48 hours could still be considered prompt. The denominator for 
24 (48) hours should be all individuals reporting fever, visited 2 (3) or more days after symptoms 
began. Surveys must therefore also ask when symptoms began. 
 The indicator should be collected by SEG in view of the emphasis placed on equity by both the 
Kenyan MOH, and RBM. All surveys should therefore include the standard asset indicators from 
the Kenya (K)DHS (collection of asset indicators is much quicker and more reliable than 
collection of income or expenditure data). Households should then be allocated to national SEGs 
on the basis of national KDHS weights. This is preferable to calculating a study specific asset 
index and SEGs, as, for example, households in socio-economic quintile 3 in one study area 
could be in quintile 5 in another. 
 The indicator should be collected by treatment source (e.g. public, faith-based organisations 
(FBOs) and commercial facilities, pharmacies, other retail outlets and CORPs) in order to know 
through which channels the intervention is achieving its goals. 
 Study teams should choose a sample size capable of detecting at least a 20 percentage point 
increase in ACT coverage in the target group (5% significance, 80% power, allowing for clustering 
if such sampling is used). As a rough guide, assuming an initial proportion of 11% 
(KEMRI/Wellcome Trust, 2007), with a simple random sample of households this would require 
a minimum of 65 childhood fevers per group (before and after, or control and intervention). In 
areas with moderate to high malaria transmission you are likely to need to visit between 2 and 4 
households to find one childhood fever, meaning that you should sample at least 260 
households in each group. If a cluster design is used it would be conservative to double this 
requirement to 520 households per group.  
 It is recommended that tools such as picture boards are used to facilitate recall of drugs used. 
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Indicator 2: The proportion of children under 5 years with fever taking a first line ACT who adhered to 
the treatment dose, by source 
 Adherence is important in both treatment efficacy and reducing the risk of the development of 
resistance. 
 As ACT is a 3 day course, the denominator should be individuals interviewed 3 or more days 
after ACT treatment began. 
 The indicator should be measured by source to indicate any variations in adherence across 
treatment types. 
 Adherence will be defined as taking the quantity of drug specified in MOH guidelines by age 
group over 3 days (i.e. excludes both under and over dosing). 
 Timing of doses within the 3 days will not be considered due to problems of precise time recall. 
Indicator 3: The proportion of children under 5 years with fever who took an anti-malarial 
monotherapy in the past 2 weeks 
 This assesses whether the intervention has succeeded in crowding monotherapies from the 
market, which are undesirable because they create competition that may decrease the demand 
for more effective combination therapies such as ACTs. The availability of artemisinin 
monotherapies increases the likelihood of the development of resistance to artemisinin, thus 
reducing the useful therapeutic life (UTL) of the ACTs.  
Indicator 4: The proportion of children under 5 years with fever in the past 2 weeks who sought 
treatment by source (e.g. from public, mission & commercial health facilities, pharmacies, other retail 
outlets, CORPs, traditional healers and other sources) 
 
 This indicator will allow assessment of any changes in treatment seeking patterns as a result of 
the intervention, for example whether there is a shift away from facilities, or from shops to 
CORPs, or an overall increase in the proportion seeking any care. 
 The indicator covers any use of each outlet type, irrespective of the order in which they were 
used. One child may therefore use more than one source. 
A2: Provider Survey Indicators 
Indicator 5: The median price charged by non-facility outlets for a first line ACT by age band 
 The price charged is important in order to assess affordability and whether subsidies are being 
passed onto final users i.e. are providers adhering to recommended retail prices or to free 
provision depending on the intervention design.  
 We propose collecting drug price data from the provider survey rather than the household 
survey because of the difficulties of recall of costs in household surveys, the problems of 
separating the cost of a single drug from other payments, and problems of standardisation due 
to variation in patient age and dose obtained. It is possible that providers may not admit 
diverging from recommended prices under direct questioning, so an optional alternative is to 
validate price data through the patient- provider encounter indicators – see below. 
 The median rather than the mean is generally used for cost and price data as the data tend to be 
skewed. 
 
Indicator 6: The proportion of non-facility outlets with no expired first line ACT available in stock 
Indicator 7: The proportion of non-facility outlets reporting stock outs of the first line ACT within the 
past 2 weeks 
 
 
 
vii 
 
 A stock out is regarded as any period of time the facility does not contain stock. Restricting stock 
outs to a minimum period of time may complicate data collection in addition, an efficient supply 
chain should ensure that drugs are always available for customers to purchase.  
 
Indicator 8: The proportion of non-facility outlets storing first line ACT appropriately 
 
  Storage conditions include: (1) Off floor, (2) Out of direct sunlight, (3) Dry area, (4) Away from 
foodstuff, (5) All conditions met.  “Appropriate storage” is defined as item (5) i.e. all storage 
conditions (1-4) have been met.  
 
Indicator 9: The proportion of non-facility outlets that have copies of the materials/ job aids required 
by the intervention (e.g. leaflets, posters, guidelines) 
  
 
A3: Intervention Cost Indicators 
 
Ideally one would want cost data from all pilots in order to compare: 
Indicator 10: Implementation cost per intervention area  
 The cost of the intervention will provide information on the size of budget required to roll out a 
similar intervention either at a regional or national level. 
 Costs should take into account all items that were paid for during the planning and rollout of the 
intervention. These include for example, costs of purchasing the anti-malarial drugs, costs of 
transport of staff and goods to and from intervention sites, salaries paid to all staff who played a 
part in planning and implementation of the intervention, and costs incurred from the 
development of information, education and communication materials. 
 
Indicator 11: The cost-effectiveness in terms of the incremental cost per additional child receiving 
prompt ACT treatment 
However, there are a number of challenges: 
 Pilots tend to operate on a small scale and therefore costs may not be representative of larger 
scale operations, when costs per capita may fall significantly.  
 Considerable effort is required to ensure that cost data collected are comparable. 
 Cost data collection and analysis requires specific skills that may not be available to all partners. 
A costing consultant will therefore be hired by the MOH to work with each team to estimate costs for 
scaled up operation of each pilot. This will facilitate the use of standardised methods and unit costs 
where appropriate, and avoid basing policy decisions on unrepresentative costs from differing small 
scale operations. It is therefore compulsory for all pilots to keep records of resource use, and to 
collaborate with the MOH in any costing analysis required. 
 
A4: Pharmacovigilance Indicators 
Pilots will be required to collaborate with regulatory authorities (PPB, MOH) to ensure that any 
pharmacovigilance requirements are met within their intervention design. 
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B. Optional complementary indicators 
 
B1: Household Survey Indicators 
 Indicators 1-4 could be adapted to consider Individuals of 5 years and over 
 Indicator 1 could be adapted to consider all antimalarials, or all “effective” antimalarials 
 The proportion of non-target household members receiving intervention ACT (e.g. adults 
receiving paediatric ACT if ACT is targeted at children only; pregnant women receiving ACT) 
 Household cost of fever episode (for all completed episodes) 
 The proportion of households within 30 minutes to 1 hour travel time from a first line ACT source 
 The proportion of caregivers with knowledge of malaria symptoms, danger signs, ACT and 
correct ACT dose for 2 year old 
B2: Provider Survey Indicators 
 Total volume of ACT distributed per capita in public and private sectors 
 The proportion of sub-locations with at least one ACT source 
 Availability of public sector ACT in inappropriate outlets 
 Availability of private sector intervention ACT in inappropriate outlets 
 The proportion of non-facility outlets with first line ACT stock records that correspond with 
physical counts 
 
The above indicators require a detailed understanding of a variety of factors for all service providers in 
the locality including the numbers, nature and antimalarial stocks. This is unlikely to be feasible for all 
studies. 
 
B3: Patient- Provider Encounters Indicators 
In addition to the household and provider surveys, it is necessary to include some evaluation of patient-
provider interaction to give better information on actual (rather than self-reported) provider behaviour. 
Patient-provider interaction can be assessed by a number of methods including the following: 
 
 Direct observation requires data collectors to directly observe the behaviour of the provider for 
the purpose of describing over the counter prescribing and dispensing practices. 
 Mystery shopper study, where data collectors pose as ordinary customers. It provides similar 
information to direct observation, except the observer does not have to stay at the site for a 
substantial period of time; the potential bias from observation is eliminated and the scenarios 
assessed can be standardised between outlets. This technique does however raise some ethical 
concerns because informed consent is not obtained from the medicine seller before the study is 
conducted. 
 Exit interviews provide information to determine how well each patient/caregiver understood 
the instructions given by the provider and also can be used as a record of reported patient 
provider interactions. 
 Vignette surveys. These are short hypothetical scenarios described to the interviewee with the 
intention of eliciting a response from them. For example ‘what would you do if a care giver 
presented with a 2 year old child with fever?’. The response is used to portray perceptions, 
opinions, beliefs and attitudes of the interviewee. The responses however do not provide any 
information on the actions of the care giver if presented with a similar real life situation as 
beliefs do not always translate into action.  
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 Management information systems involve using retrospective data collected by the non-facility 
outlet to determine the prescribing and dispensing practices of the provider 
 
Data will not be strictly comparable between the above methods. However, no single method is 
possible in all studies for practical reasons. For example, it would not be efficient to do an exit interview 
where there are only a few customers per day; neither is it possible to use mystery shoppers at a clinic. 
Each study should therefore include the method most suitable to them.  
 
Indicators for the patient provider encounters include: 
 
 The proportion of non-facility outlet staff that dispense an appropriate first line ACT to patients 
presenting with fever 
 The proportion of non-facility outlet staff that dispense the correct dose of first line ACT to 
patients presenting with fever  
 The proportion of non-facility outlets that provide appropriate information to patients/ 
caregivers on how to give/ take the first line ACT 
 The proportion of encounters where non-facility outlet staff asked one or more clinical questions 
to determine severity of malaria 
 The proportion of non facility outlet staff who told patients/ caregivers about any signs of 
progressive illness and recommended a referral visit to a doctor or clinic if the signs appear 
 The median price charged for an ACT dose by age group 
 
B4: Qualitative Data Indicators 
It is also recommended that studies include qualitative data collection activities such as focus group 
discussions and in-depth interviews with household members, providers and others involved in the 
distribution chain. These will complement, validate and help interpret the quantitative indicators, 
providing a richer understanding of the reasons behind achievements and constraints in 
implementation. Qualitative data may also be used to inform the design of quantitative instruments. 
 
B5: Diagnostic Indicators 
Diagnosis can be either clinical (presumptive) or parasitologically confirmed (microscopy or rapid 
diagnostic tests). It is likely that a mix of diagnostic approaches will be used across the studies. Where 
parasitologically confirmed diagnosis is used in an intervention, the following indicators should be 
evaluated: 
 The proportion of non-facility outlets staff able to confirm a malaria diagnosis according to 
national guidelines using the approved diagnostic 
 The proportion of non-facility outlet patients who undergo a malaria diagnostic test 
 The sensitivity and specificity of a diagnostic test. Diagnostics should be of high sensitivity since 
false negatives may result in failure to treat, and of high specificity to avoid over diagnosis and 
subsequent over treatment. 
 The proportion of non facility outlets reporting stock outs of the approved diagnostic or 
components required for its proper functioning, within the past 2 weeks 
 
 
C. Indicators Likely to be Beyond the Scope of Pilot Studies 
 
C1: Morbidity and Mortality Indicators 
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Final health outcome measures such as number of severe malaria cases and number of malaria fatalities 
would clearly be desirable. However, they are difficult to obtain for 2 reasons: 
 
 They are relatively rare events and therefore require very large sample sizes; 
 Many severe cases and deaths are not seen at health facilities and therefore are difficult to 
identify; over 60% of deaths in Kenya and in the sub-region occur at home. 
It is therefore not expected that most studies will include these indicators. Exceptions may be large 
scale studies which could consider facility reports of severe cases, or studies taking place within 
demographic surveillance areas where community-based malaria mortality rates can be assessed based 
on verbal autopsy. 
 
C2: Drug Resistance Indicators 
Pilots are unlikely to be able to measure the impact of their intervention on drug resistance directly 
through treatment failure rates or genetic resistance markers. Measuring such outcomes would require 
large sample sizes, long time frames, and considerably increase evaluation costs in terms of collection of 
blood samples and laboratory analysis.  
 
C3: Drug Quality Indicators 
All pilots will use ACT supplies from quality certified sources and will therefore not be at risk of poor 
quality from sub-standard or fraudulent manufacturing. However, it is possible that the storage and 
handling of ACT in the supply chain could negatively affect quality, and these intermediate outcomes 
are therefore included under the provider survey. Again, additional laboratory tests would be required 
to assess the impact of storage and handling on actual quality. 
 
 
 
 
 
 
 
Summary of Compulsory Indicators 
 
No. Indicator Source 
1 The proportion of children under 5 years with fever in the past 2 
weeks who started treatment with a first line ACT within 24 and 48 
hours of fever onset, overall, by socio-economic group (SEG) and 
treatment source 
Household Survey 
2 The proportion of children under 5 years with fever taking a first line 
ACT who adhered to the treatment dose, by source 
Household Survey 
3 The proportion of children under 5 with fever who took an anti-
malarial monotherapy in the past 2 weeks 
Household Survey 
4 The proportion of children under 5 years with fever in the past 2 
weeks who sought treatment by source ( e.g. public, mission & 
commercial health facilities, pharmacies, other retail outlets, CORPs, 
traditional healers and other sources) 
Household Survey 
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5 The median price charged by non-facility outlets for a first line ACT 
by age band  
Provider Survey 
6 The proportion of non-facility outlets with no expired first line ACT 
available in stock  
Provider Survey 
7 The proportion of non-facility outlets reporting stock outs of the first 
line ACT within the past 2 weeks 
Provider Survey 
8 The proportion of non-facility outlets storing first line ACT 
appropriately 
Provider Survey 
9 The proportion of non-facility outlets that have copies of the 
materials/ job aids required by the intervention (e.g. leaflets, 
posters, guidelines) 
Provider Survey 
10 Implementation cost per intervention area Costing Study 
11 The cost-effectiveness in terms of the incremental cost per 
additional child receiving prompt ACT treatment 
Costing Study 
(effectiveness from 
household survey) 
12 To be confirmed by relevant regulatory authorities Pharmacovigilance 
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APPENDIX 5:  
PSI Intervention Timelines 
 
 
2008 2009 2010 
Activity Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan 
                          Administrative Issues 
                         Proposal ethical approval 
                         OTC Status Advocacy 
                         
                          Product 
                         Concept Design 
                         Pre-test 
                         Final design 
                         DOMC/PPB Approval 
                         Product Arrival in country 
                         Production (overpackaging) 
                         
                          Training 
                         Adaptation of diagnostic algorithm 
                         Develop Shopkeeper training manual 
                         Outlet selection & Recruitment 
                         Train shopkeepers 
                         Train IPC teams 
                         
                          Communications 
                         Develop & produce communication 
materials 
                         Develop & produce POS materials 
                         DiDisburse BTL promotional material 
                         
                          Launch 
                         Sell Into Trade 
                         Franchising/Merchandising outlets 
                         Demand creation activities (IPC) 
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APPENDIX 6 
 
Abbreviations/ Acronyms 
 
ACT Artemisinin Combination Therapy 
ADR Adverse Drug Reactions 
AIDS Acquired Immuno-Deficiency Syndrome 
AL Artemether- Lumefantrine 
AQ Amodiaquine 
CORPs Community Owned Resource Persons 
DHMT District Health Management Team 
DHS Demographic and Health Survey 
DO District Officer 
DOCH Division of Child Health 
DOMC Division of Malaria Control 
DPTWG Drug Policy Technical Working Group 
EA Enumeration Area 
EST Estimated 
FDG Focus Group Discussions 
GDP Gross Domestic Product 
GF Global Fund 
GPS Global Positioning System 
HH Households 
HIV Human Immuno-deficiency Virus 
HMM Home Management of Malaria 
HS Homestead 
IEC Information, Education and Communication 
IMCI Integrated Management of Childhood illness 
ITN Insecticide Treated Net 
Kshs Kenya Shillings 
KWTRP Kemri Wellcome Trust Research Programme 
MOH Ministry of Health  
NGO Non Governmental Organization 
NO Number 
OTC Over the Counter  
PCA Principal Component Analysis  
PMI President's Malaria Initiative 
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POM Prescription Only Medicine 
POP Population  
PPB Pharmacy and Poisons Board 
PSI Population Services International  
RBM Roll Back Malaria 
SEG Socio-economic group 
SP Sulphadoxine/ sulfalene-Pyrimethamine  
STI Sexually Transmitted Disease 
US$ United States Dollars 
WHO World Health Organization 
 
